Prostate Cancer: Management in Elderly Men Population in 2017
Prostate cancer is the most common cancer in elderly patients. Localized disease is treated following almost the standard of younger patients. However, the treatment depends on health status evaluation. Only patients in good health status with aggressive prostate cancer will benefit of curative treatment, based on the induced comorbidities. Surgery is often not the best option, based on the increased side effects with increased age, compared to external beam radiotherapy. In nonmetastatic situations, androgen deprivation monotherapy has only a minimal place, while it is the standard of care in metastatic situations. Most patients with castration-resistant disease can receive standard treatment. Early introduction of palliative care is mandatory in order to optimize the outcome. Disease aggressiveness and health status are the two main factors to consider, on top of patient’s wishes for final decision-making.
KeywordsProstate cancer Elderly Urologic oncology
- AJCC (8th ed) [Internet]. 2017. Available from: https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx.
- Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 2017;197(2S):S200–7.CrossRefPubMedGoogle Scholar
- Droz J-P, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, et al. Management of prostate cancer in elderly patients: recommendations of a Task Force of the International Society of Geriatric Oncology. Eur Urol. 2017;72:521–31. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0302283817300015CrossRefPubMedGoogle Scholar
- Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–52.PubMedGoogle Scholar
- Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015;16(7):787–94.CrossRefPubMedGoogle Scholar
- Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(24):3984–90.CrossRefGoogle Scholar
- Isenberg-Grzeda E, Huband H, Lam H. A review of cognitive screening tools in cancer. Curr Opin Support Palliat Care. 2016;11:24–31.Google Scholar
- James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–38.CrossRefPubMedGoogle Scholar
- Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2016;196:1613–8.Google Scholar
- NCCN guidelines on prostate cancer [Internet]. 2016. Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
- Noone A-M, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI, et al. Cancer incidence and survival trends by subtype using data from the surveillance epidemiology and end results program, 1992–2013. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2017;26(4):632–41.CrossRefGoogle Scholar
- Ries LAG, Krapcho M. SEER cancer statistics review, 1975–2011 [Internet]. 2014. Available from: http://seer.cancer.gov/csr/1975_2011/
- Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.CrossRefPubMedGoogle Scholar
- Tewari A, Johnson CC, Divine G, Crawford ED, Gamito EJ, Demers R, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol. 2004;171(4):1513–9.CrossRefPubMedGoogle Scholar
- University California San Francisco. Eprognosis: electronic tools. 2016. http://eprognosis.ucsf.edu/index.php. Ref Type: online Source.
- US Census Bureau DIS. International Programs, International Data Base [Internet]. [cited 2017 Jan 14]. Available from: https://www.census.gov/population/international/data/idb/worldpopgraph.php
- Vale CL, Burdett S, Rydzewska LHM, Albiges L, Clarke NW, Fisher D, et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol. 2016;17(2):243–56.CrossRefPubMedPubMedCentralGoogle Scholar